Skip to content
2000
Volume 2, Issue 1
  • ISSN: 1574-8855
  • E-ISSN: 2212-3903

Abstract

The use of dopamine agonists has increased due to their effectiveness in treating symptoms of Parkinson disease (PD) and Restless Leg Syndrome (RLS). Recently, rare but serious adverse effects have been linked to DA agonists, including sudden somnolence, cardiac valvulopathy and repetitive behaviors. Clinicians are in a difficult situation because of insufficient information to make clear recommendations to patients. We review these controversies, discuss pathophysiology and report current practices in light of such uncertainty.

Loading

Article metrics loading...

/content/journals/cdth/10.2174/157488507779422347
2007-01-01
2025-10-22
Loading full text...

Full text loading...

/content/journals/cdth/10.2174/157488507779422347
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test